The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China; Department of Oral & Maxillofacial Head Neck Oncology, School & Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China.
The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China.
Int Rev Cell Mol Biol. 2023;378:233-264. doi: 10.1016/bs.ircmb.2023.03.007. Epub 2023 Apr 10.
Myeloid-derived suppressor cells (MDSCs) are a group of heterogenous immature myeloid cells with potent immune suppressive properties that not only constrain anti-tumor immune activation and functions, promote tumor progression, but also contribute to treatment resistance and tumor relapse. Targeting MDSCs may be a promising new cancer treatment method, but there is still a problem of low treatment efficiency. Combined application with radiotherapy may be a potential method to solve this problem. Drug delivery systems (DDSs) provide more efficient targeted drug delivery capability and can reduce the toxicity and side effects of drugs. Recent advance in DDSs targeting development, recruitment, differentiation, and elimination of MDSCs have shown promising effect in reversing immune inhibition and in overcoming radiotherapy resistance. In this review, we systematically summarized DDSs applied to target MDSCs for the first time, and classified and discussed it according to its different mechanisms of action. In addition, this paper also reviewed the biological characteristics of MDSCs and their role in the initiation, progression, and metastasis of cancer. Moreover, this review also summarizes the role of DDSs targeting MDSCs in radiosensitization. Finally, the future development of DDSs targeting MDSCs is also prospected.
髓系来源的抑制性细胞(MDSCs)是一群具有强大免疫抑制特性的异质性未成熟髓系细胞,它们不仅限制了抗肿瘤免疫激活和功能,促进了肿瘤的进展,而且还导致了治疗耐药和肿瘤复发。针对 MDSCs 可能是一种有前途的新癌症治疗方法,但仍存在治疗效率低的问题。与放射治疗联合应用可能是解决这一问题的潜在方法。药物传递系统(DDS)提供了更有效的靶向药物传递能力,并可以降低药物的毒性和副作用。最近在针对 MDSCs 的发育、募集、分化和消除的 DDS 方面的进展,在逆转免疫抑制和克服放疗抵抗方面显示出了有希望的效果。在这篇综述中,我们首次系统地总结了用于靶向 MDSCs 的 DDS,并根据其不同的作用机制对其进行了分类和讨论。此外,本文还回顾了 MDSCs 的生物学特性及其在癌症的发生、进展和转移中的作用。此外,本文还总结了 DDS 靶向 MDSCs 在放射增敏中的作用。最后,还对 DDS 靶向 MDSCs 的未来发展进行了展望。